Masur Argues Myriad Ruling Will Be Positive for Many Biotech Firms

A Supreme Court loss on human gene patents is just what Myriad—and the biotech industry—need
Rachel Feltman
June 13, 2013

The US Supreme Court today ruled that Myriad, the US biotech company that holds a monopoly on testing for a set of breast-cancer related genes, can’t hold a patent on genetic material. But after the news broke, Myriad’s stock shot up...

Even with the genes themselves freed up for use by other companies, it could take years for other testing options to hit the market. That’s partly because of the work involved to create related cDNA. And meanwhile Myriad still has its cDNA patents protected until 2015. Jonathan Masur, professor of law at the University of Chicago, argued last week in The New York Times that such a ruling would be the best of both worlds. Masur in an interview with Quartz today said the decision balances between providing an incentive